8-K Announcements
6Material company update
May 26, 2026·SEC
Material company update
May 14, 2026·SEC
Material company update
May 1, 2026·SEC
Senti Biosciences, Inc.(SNTI)Earnings, Financials & Key Ratios
SNTI•NASDAQ
Price updated Jun 19, 2026
AboutSenti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to respective cellular environments. Its synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells to target particularly challenging liquid and solid tumor oncology indications. The company's lead programs include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells, while sparing the healthy bone marrow; and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma (HCC). It also develops SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer (CRC) cells, while sparing healthy cells in the body. The company was founded in 2016 and is based in South San Francisco, California.Show more
- Revenue$22K
- EBITDA-$60M-8.9%
- Net Income-$61M-16.4%
- EPS (Diluted)-2.73+76.2%
- Gross Margin-16431.82%
- EBITDA Margin-273136.36%
- Operating Margin-289668.18%
- Net Margin-279263.64%
- ROE-393.35%-244.9%
SNTI Key Insights
Senti Biosciences, Inc. (SNTI) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗High debt to equity ratio of 5.2x
- ✗Profits declining 25.3% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Sales declining 43.8% over 5 years
- ✗Shares diluted 100.0% in last year
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when SNTI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SNTI Price & Volume
Senti Biosciences, Inc. (SNTI) stock price & volume — 10-year historical chart
Loading chart...
SNTI Growth Metrics
Senti Biosciences, Inc. (SNTI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-43.85%
3 Years-81.15%
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM5.92%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM83.95%
Return on Capital
10 Years-69.58%
5 Years-70.43%
3 Years-79.02%
Last Year-104.52%
SNTI Recent Earnings
Senti Biosciences, Inc. (SNTI) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (67%)●Beat Revenue 3/12 qtrs (60%)
Q2 2026Latest
May 14, 2026Metric
Actual
Est
EPS
$0.14+61.1%
$0.36
Rev
—
$20,534
Q2 2026
Mar 27, 2026Metric
Actual
Est
EPS
$0.38+11.6%
$0.43
Rev
$22,000-97.8%
$1M
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.69-16.9%
$0.59
Rev
—
$250,000
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.56+37.8%
$0.90
Rev
—
$500,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $0.14vs $0.36+61.1% | —vs $20,534 |
| Q2 2026 | Mar 27, 2026 | $0.38vs $0.43+11.6% | $22,000vs $1M-97.8% |
| Q4 2025 | Nov 13, 2025 | $0.69vs $0.59-16.9% | —vs $250,000 |
| Q3 2025 | Aug 7, 2025 | $0.56vs $0.90+37.8% | —vs $500,000 |
Based on last 12 quarters of dataView full earnings history →
SNTI Peer Comparison
Senti Biosciences, Inc. (SNTI) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 | |
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 SGMO | 74.57M | 0.18 | -0.41 | -31.57% | -356.89% | -28.92% | ||
 EDIT | 263.37M | 2.69 | -1.49 | 25.39% | -281.59% | -6.77% | 2.81 | |
 ILMN | 24.6B | 161.93 | 29.71 | -0.78% | 19.43% | 32.84% | 0.94 | |
 TMO | 172.66B | 464.61 | 26.19 | 3.91% | 15.18% | 13.23% | 0.76 |
Compare SNTI vs Peers
Senti Biosciences, Inc. (SNTI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SNTI Income Statement
Senti Biosciences, Inc. (SNTI) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 85K | 394K | 2.29M | 3.29M | 1.98M | 0 | 22K | 38K |
Revenue Growth % | - | 363.53% | 481.47% | 43.43% | -39.81% | -100% | - | - |
Cost of Goods Sold | 14.52M | 0 | 0 | 0 | 0 | 0 | 3.64M | 2.37M |
COGS % of Revenue | 17087.06% | - | - | - | - | - | 16531.82% | - |
Gross Profit | -14.44M▲ 0% | 394K▲ 102.7% | 2.29M▲ 481.5% | 3.29M▲ 43.4% | 1.98M▼ 39.8% | 0▼ 100.0% | -3.62M▲ 0% | -2.33M▲ 0% |
Gross Margin % | -16987.06% | 100% | 100% | 100% | 100% | - | -16431.82% | -6134.21% |
Gross Profit Growth % | - | 102.73% | 481.47% | 43.43% | -39.81% | -100% | - | - |
Operating Expenses | 7.39M | 25.09M | 42.74M | 65.37M | 94.7M | 61.04M | 60.11M | 56.5M |
OpEx % of Revenue | 8696.47% | 6367.51% | 1865.43% | 1989.35% | 4787.92% | - | 273236.36% | - |
Selling, General & Admin | 7.34M | 9.3M | 21.25M | 37.63M | 34.87M | 23.51M | 26.16M | 24.13M |
SG&A % of Revenue | 8638.82% | 2361.42% | 927.54% | 1145.25% | 1762.79% | - | 118922.73% | - |
Research & Development | 14.52M | 15.96M | 21.96M | 28.14M | 32.15M | 34.36M | 37.59M | 33.36M |
R&D % of Revenue | 17087.06% | 4049.75% | 958.4% | 856.51% | 1625.38% | - | 170845.45% | - |
Other Operating Expenses | 0 | -172K | -470K | -408K | 27.69M | 3.17M | -3.64M | -747K |
Operating Income | -21.78M▲ 0% | -24.69M▼ 13.4% | -40.45M▼ 63.8% | -62.08M▼ 53.5% | -92.73M▼ 49.4% | -61.04M▲ 34.2% | -63.73M▼ 4.4% | -58.83M▲ 0% |
Operating Margin % | -25625.88% | -6267.51% | -1765.43% | -1889.35% | -4687.92% | - | -289668.18% | -154810.53% |
Operating Income Growth % | - | -13.37% | -63.79% | -53.5% | -49.36% | 34.17% | -4.4% | - |
EBITDA | -21.36M | -22.71M | -37.44M | -58.16M | -87.3M | -55.19M | -60.09M | -55.09M |
EBITDA Margin % | -25123.53% | -5763.71% | -1634.05% | -1770.05% | -4413.45% | - | -273136.36% | -144984.21% |
EBITDA Growth % | - | -6.34% | -64.85% | -55.37% | -50.09% | 36.78% | -8.88% | 0.33% |
D&A (Non-Cash Add-back) | 427K | 1.99M | 3.01M | 3.92M | 5.43M | 5.85M | 3.64M | 3.73M |
EBIT | -21.78M | -24.69M | -40.45M | -62.08M | -66.77M | -60.73M | -63.73M | -56.76M |
Net Interest Income | 674K | 88K | 11K | 1.7M | 2.86M | 0 | 927K | 634K |
Interest Income | 674K | 88K | 11K | 1.7M | 2.86M | 0 | 927K | 634K |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 625K | 4.83M | -14.87M | 12.42M | 9.32M | 8.25M | 2.29M | 7.28M |
Pretax Income | -21.16M▲ 0% | -19.86M▲ 6.1% | -55.32M▼ 178.5% | -49.66M▲ 10.2% | -83.41M▼ 67.9% | -52.79M▲ 36.7% | -61.44M▼ 16.4% | -51.55M▲ 0% |
Pretax Margin % | -24890.59% | -5041.12% | -2414.62% | -1511.41% | -4216.68% | - | -279263.64% | -135650% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -21.16M▲ 0% | -19.86M▲ 6.1% | -55.32M▼ 178.5% | -58.21M▼ 5.2% | -71.06M▼ 22.1% | -52.79M▲ 25.7% | -61.44M▼ 16.4% | -51.55M▲ 0% |
Net Margin % | -24890.59% | -5041.12% | -2414.62% | -1771.45% | -3592.42% | - | -279263.64% | -135650% |
Net Income Growth % | - | 6.12% | -178.52% | -5.23% | -22.07% | 25.71% | -16.38% | 5.92% |
Net Income (Continuing) | -21.16M | -19.86M | -55.32M | -49.66M | -83.41M | -52.79M | -61.44M | -51.55M |
Discontinued Operations | 0 | 0 | 0 | -8.54M | 12.35M | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -15.57▲ 0% | -4.55▲ 70.8% | -12.67▼ 178.5% | -13.25▼ 4.6% | -20.94▼ 58.0% | -11.49▲ 45.1% | -2.73▲ 76.2% | -1.66▲ 0% |
EPS Growth % | - | 70.78% | -178.46% | -4.58% | -58.04% | 45.13% | 76.24% | 83.95% |
EPS (Basic) | -15.57 | -4.55 | -12.67 | -13.25 | -20.94 | -11.49 | -2.73 | - |
Diluted Shares Outstanding | 1.36M | 4.37M | 4.37M | 4.39M | 4.44M | 4.6M | 224.83M | 30.97M |
Basic Shares Outstanding | 1.36M | 4.37M | 4.37M | 4.39M | 4.44M | 4.6M | 224.83M | 30.97M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
SNTI Balance Sheet
Senti Biosciences, Inc. (SNTI) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 18.76M | 31.71M | 58.75M | 102.58M | 71.2M | 58.96M | 23.27M | 14.79M |
Cash & Short-Term Investments | 17.83M | 30.54M | 56.03M | 98.56M | 35.93M | 48.28M | 16.42M | 8.94M |
Cash Only | 5.3M | 30.54M | 56.03M | 57.62M | 35.93M | 48.28M | 16.42M | 8.94M |
Short-Term Investments | 12.53M | 0 | 0 | 40.94M | 0 | 0 | 0 | 0 |
Accounts Receivable | 78K | 317K | 483K | 626K | 17.7M | 1.8M | 323K | 172K |
Days Sales Outstanding | 334.94 | 293.67 | 76.95 | 69.53 | 3.27K | - | 5.36K | 10.41K |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 853K | 830K | 1.43M | 1.52M | 237K | 584K | 6.53M | 5.68M |
Total Non-Current Assets | 16.59M | 16.64M | 37.95M | 78.21M | 48.28M | 38.88M | 27.95M | 23.45M |
Property, Plant & Equipment | 16.59M | 16.14M | 33.08M | 74.55M | 41.61M | 35.24M | 24.4M | 0 |
Fixed Asset Turnover | 0.01x | 0.02x | 0.07x | 0.04x | 0.05x | - | 0.00x | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 3.26M | 3.37M | 4.64M | 0 | 3.53M | 3.53M |
Other Non-Current Assets | -16.59M | 497K | 1.62M | 293K | 2.03M | 3.64M | 19K | 23.45M |
Total Assets | 35.84M▲ 0% | 48.34M▲ 34.9% | 96.7M▲ 100.0% | 180.79M▲ 87.0% | 119.48M▼ 33.9% | 97.84M▼ 18.1% | 51.22M▼ 47.6% | 38.24M▲ 0% |
Asset Turnover | 0.00x | 0.01x | 0.02x | 0.02x | 0.02x | - | 0.00x | 0.00x |
Asset Growth % | - | 34.88% | 100.02% | 86.96% | -33.91% | -18.11% | -47.65% | -131.31% |
Total Current Liabilities | 4.31M | 4.87M | 14.54M | 18.05M | 12.67M | 13.15M | 13.97M | 14.27M |
Accounts Payable | 1.2M | 914K | 5.19M | 2.27M | 1.25M | 1.45M | 2.94M | 0 |
Days Payables Outstanding | 30.08 | - | - | - | - | - | 295.35 | 220.86 |
Short-Term Debt | 0 | 0 | 1.74M | 0 | 0 | 0 | 5.33M | 5.89M |
Deferred Revenue (Current) | 0 | 0 | 1.66M | 799K | 989K | 660K | 43K | 403K |
Other Current Liabilities | 3.11M | 2.37M | 3.29M | 9.26M | 3.94M | 2.55M | 5.66M | 8.38M |
Current Ratio | 4.36x | 6.52x | 4.04x | 5.68x | 5.62x | 4.49x | 1.67x | 1.04x |
Quick Ratio | 4.36x | 6.52x | 4.04x | 5.68x | 5.62x | 4.49x | 1.67x | 1.04x |
Cash Conversion Cycle | - | - | - | - | - | - | - | 10.19K |
Total Non-Current Liabilities | 0 | 102.19M | 21.78M | 35.48M | 39.9M | 59.05M | 31.66M | 21.41M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13.25M |
Capital Lease Obligations | 0 | 12.53M | 20.99M | 35.1M | 33.54M | 28.89M | 23.56M | 26.33M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 89.66M | 619K | 373K | 6.36M | 30.16M | 8.1M | 8.16M |
Total Liabilities | 17.88M | 107.06M | 36.33M | 53.53M | 52.57M | 72.19M | 45.63M | 35.68M |
Total Debt | 0 | 14.05M | 22.73M | 37.09M | 37.67M | 33.64M | 28.89M | 19.14M |
Net Debt | -5.3M | -16.49M | -33.3M | -20.53M | 1.74M | -14.64M | 12.47M | 10.21M |
Debt / Equity | - | - | 0.38x | 0.29x | 0.56x | 1.31x | 5.17x | 7.46x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.35x |
Net Debt / EBITDA | - | - | - | - | - | - | - | -0.19x |
Interest Coverage | - | - | - | - | - | - | - | - |
Total Equity | 17.96M▲ 0% | -58.71M▼ 426.8% | 60.38M▲ 202.8% | 127.26M▲ 110.8% | 66.91M▼ 47.4% | 25.65M▼ 61.7% | 5.59M▼ 78.2% | 2.56M▲ 0% |
Equity Growth % | - | -426.82% | 202.83% | 110.78% | -47.42% | -61.67% | -78.21% | -264.82% |
Book Value per Share | 13.22 | -13.45 | 13.83 | 28.96 | 15.08 | 5.58 | 0.02 | 0.08 |
Total Shareholders' Equity | 17.96M | -58.71M | 60.38M | 127.26M | 66.91M | 25.65M | 5.59M | 2.56M |
Common Stock | 1K | 1K | 0 | 4K | 5K | 1K | 3K | 3K |
Retained Earnings | -39.9M | -59.76M | -115.08M | -173.29M | -244.34M | -297.13M | -358.57M | -362.79M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 1K | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SNTI Cash Flow Statement
Senti Biosciences, Inc. (SNTI) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -18.38M | -24.17M | -34.63M | -34.9M | -52.4M | -41.4M | -43.44M | -36.88M |
Operating CF Margin % | -21621.18% | -6135.28% | -1511.79% | -1061.96% | -2648.89% | - | -197472.73% | - |
Operating CF Growth % | - | -31.53% | -43.28% | -0.75% | -50.15% | 20.99% | -4.94% | 19.1% |
Net Income | -21.16M | -19.86M | -55.32M | -58.22M | -71.06M | -52.79M | -61.44M | -51.55M |
Depreciation & Amortization | 1.4M | 1.99M | 3.01M | 3.92M | 5.43M | 5.85M | 3.64M | 4.52M |
Stock-Based Compensation | 205K | 272K | 2.29M | 16.39M | 9.67M | 1.75M | 5.71M | 4.27M |
Deferred Taxes | -329K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 1.38M | -4.79M | 14.76M | -10.89M | -1.1M | -256K | 5.09M | -1.73M |
Working Capital Changes | 124K | -1.77M | 615K | 13.9M | 4.67M | 4.04M | 3.56M | 7.62M |
Change in Receivables | 124K | -10K | -395K | -131K | -929K | -727K | 210K | 1.45M |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | -324K | -617K | 186K | -290K | 797K | 1.74M | -505K |
Cash from Investing | 3.75M | 11.36M | -5.54M | -81.96M | 30.08M | 34K | -184K | -58K |
Capital Expenditures | -2M | -1.16M | -5.54M | -41.37M | -12.04M | -26K | -196K | -196K |
CapEx % of Revenue | 2348.24% | 294.67% | 241.95% | 1259.1% | 608.59% | - | 890.91% | 515.79% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 12K | 24K |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 5.75M | 0 | 0 | 0 | 105K | 60K | 0 | 114K |
Cash from Financing | 14.01M | 38.05M | 68.44M | 118.55M | 779K | 53.73M | 11.76M | 12.06M |
Debt Issued (Net) | 0 | 8M | 0 | 5.17M | -108K | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 30M | 66.95M | 728K | 512K | 49.06M | 8.71M | 9.12M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 14.01M | 51K | 1.48M | 112.65M | 375K | 4.67M | 3.05M | 2.93M |
Net Change in Cash | 5.8M▲ 0% | 25.24M▲ 335.3% | 28.26M▲ 12.0% | 1.7M▼ 94.0% | -21.54M▼ 1370.0% | 12.37M▲ 157.4% | -31.87M▼ 357.7% | -24.88M▲ 0% |
Free Cash Flow | -20.37M▲ 0% | -25.33M▼ 24.3% | -40.18M▼ 58.6% | -76.27M▼ 89.8% | -64.43M▲ 15.5% | -41.42M▲ 35.7% | -43.64M▼ 5.4% | -37.07M▲ 0% |
FCF Margin % | -23969.41% | -6429.95% | -1753.73% | -2321.06% | -3257.48% | - | -198363.64% | -97555.26% |
FCF Growth % | - | -24.34% | -58.59% | -89.83% | 15.52% | 35.71% | -5.35% | 15.32% |
FCF per Share | -15.00 | -5.80 | -9.20 | -17.35 | -14.52 | -9.01 | -0.19 | -1.20 |
FCF Conversion (FCF/Net Income) | 0.87x | 1.22x | 0.63x | 0.60x | 0.74x | 0.78x | 0.71x | 0.72x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SNTI Key Ratios
Senti Biosciences, Inc. (SNTI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -6652.92% | -62.04% | -73.19% | -114.06% | -393.35% | -503.79% |
Return on Invested Capital (ROIC) | - | - | -69.6% | -79.31% | -114.93% | -328.79% | -193.48% |
Gross Margin | 100% | 100% | 100% | 100% | - | -16431.82% | -6134.21% |
Net Margin | -5041.12% | -2414.62% | -1771.45% | -3592.42% | - | -279263.64% | -135650% |
Debt / Equity | - | 0.38x | 0.29x | 0.56x | 1.31x | 5.17x | 7.46x |
FCF Conversion | 1.22x | 0.63x | 0.60x | 0.74x | 0.78x | 0.71x | 0.72x |
Revenue Growth | 363.53% | 481.47% | 43.43% | -39.81% | -100% | - | - |
Related:SNTI Dividend History·SNTI Revenue History·SNTI Price History·SNTI P/E History·SNTI Financial Ratios·SNTI Institutional Holders
SNTI SEC Filings & Documents
Senti Biosciences, Inc. (SNTI) SEC filings — annual & quarterly reports (10-K, 10-Q)
SNTI Frequently Asked Questions
Senti Biosciences, Inc. (SNTI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Senti Biosciences, Inc. (SNTI) reported $0.0M in revenue for fiscal year 2025. This represents a 55% decrease from $0.1M in 2019.
Senti Biosciences, Inc. (SNTI) grew revenue by 0.0% over the past year. Growth has been modest.
Senti Biosciences, Inc. (SNTI) reported a net loss of $51.5M for fiscal year 2025.
Dividend & Returns
Senti Biosciences, Inc. (SNTI) has a return on equity (ROE) of -393.4%. Negative ROE indicates the company is unprofitable.
Senti Biosciences, Inc. (SNTI) had negative free cash flow of $37.1M in fiscal year 2025, likely due to heavy capital investments.